You are here

Positive Results Reported for Iron-Delivery Drug in Phase III Trial

Hemoglobin maintained without increasing stored iron in hemodialysis patients (July 11)

Positive results have been reported from a long-term phase III efficacy study of SFP (Rockwell Medical), an investigational iron-delivery drug for the treatment of iron deficiency in patients with chronic kidney disease receiving hemodialysis.

SFP met the study’s primary endpoint, demonstrating a statistically significant mean change in hemoglobin from baseline to end-of-treatment. In addition, the drug met key secondary endpoints, including the maintenance of hemoglobin, the maintenance of reticulocyte hemoglobin, and an increase in serum iron pre- to post-treatment without an increase in ferritin.

The results of this study provide clinical data required for the filing of a new drug application (NDA) with the FDA.

The CRUISE-1 study met its primary efficacy endpoint, which was a change in hemoglobin from baseline to end-of-treatment between the SFP and placebo groups. The mean difference between SFP and placebo was 3.6 g/L in favor of SFP (P = 0.011).

At baseline, the two treatment groups had similar hemoglobin levels (109.6 g/L SFP and 109.0 g/L placebo). The mean adjusted change from baseline hemoglobin to the end of the randomized treatment period in the SFP group was 0.6 g/L. In the placebo group, there was a statistically significant decline of 3.0 g/L.

Reticulocyte hemoglobin, a marker of iron delivery to the bone marrow, was maintained at baseline levels in the SFP group during the randomized treatment, compared with a significant decrease in the placebo group. At end-of-treatment, there was a statistically significant 2.1% difference in favor of SFP (P

Serum ferritin, a marker of tissue iron stores, declined by 14.7% from baseline in the SFP arm, whereas the ferritin level declined by 28.2% in the placebo group (P

SFP is an iron compound that is delivered to hemodialysis patients via dialysate, replacing the 5 to 7 mg of iron lost during a dialysis treatment. SFP is introduced into the sodium bicarbonate concentrate that subsequently is mixed into dialysate.

Source: Rockwell Medical; July 11, 2013.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs